MOTS-c Black / African Ancestry Documented Efficacy Gaps

What Is MOTS-c and Why Does Ancestry Matter?

MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) first identified in 2015 by Lee et al. At the University of Southern California. The peptide is encoded within the 12S rRNA region of mitochondrial DNA and functions as an endogenous metabolic regulator 1. Unlike nuclear-encoded proteins, MOTS-c inherits exclusively through the maternal line, meaning mitochondrial haplogroup variation directly shapes its genetic context.

Mitochondrial Haplogroups and African Ancestry

Human mitochondrial DNA is classified into haplogroups that track maternal lineage. Populations of African descent predominantly carry L-lineage haplogroups (L0, L1, L2, L3), which represent the deepest branches of the human mitochondrial phylogenetic tree 2. These haplogroups harbor single-nucleotide polymorphisms (SNPs) within the 12S rRNA gene region where MOTS-c is encoded. A study published in the American Journal of Human Genetics mapped over 4,000 mtDNA sequences and confirmed that L-lineage haplogroups carry distinct variants in the 12S rRNA locus 3.

Why This Creates an Evidence Gap

No published clinical trial of MOTS-c has reported outcomes stratified by race or mitochondrial haplogroup. The original murine data from Lee et al. Used C57BL/6 mice only 1. Early-phase human peptide studies have overwhelmingly enrolled participants of European or East Asian ancestry. This means the entire efficacy dataset for MOTS-c lacks representation from the population whose mitochondrial genome is most divergent from the studied groups.

The Metabolic Field in Black / African Ancestry Populations

Black and African ancestry adults in the United States face disproportionate cardiometabolic burden. Understanding this context is necessary to evaluate whether MOTS-c's observed benefits can be extrapolated.

Insulin Resistance and Diabetes Prevalence

The CDC's National Diabetes Statistics Report (2022) found that non-Hispanic Black adults had a diagnosed diabetes prevalence of 12.1%, compared with 7.4% among non-Hispanic White adults 4. NHANES data show that Black adults exhibit higher fasting insulin and greater HOMA-IR scores even after adjusting for BMI 5. MOTS-c's primary mechanism targets insulin sensitivity through AMPK activation 1. A population with higher baseline insulin resistance could theoretically derive greater absolute benefit from MOTS-c, or could require dose adjustment to achieve equivalent pharmacodynamic effect. Neither hypothesis has been tested.

Hypertension and the ACE-Inhibitor Parallel

Black adults have a 42% prevalence of hypertension versus 28% in White adults, per AHA/ACC 2017 guidelines 6. The pharmacogenomic precedent here is instructive. ACE inhibitors produce smaller blood pressure reductions in Black patients compared with White patients, a finding replicated across multiple RCTs including ALLHAT (N=33,357) 7. This differential response is attributed to lower circulating renin levels and distinct neurohormonal profiles. While MOTS-c operates through a different pathway (AMPK/folate-methionine rather than renin-angiotensin), the ACE-inhibitor precedent demonstrates that metabolic drugs can produce clinically meaningful efficacy gaps across ancestral groups.

Chronic Kidney Disease Risk

Black adults progress to end-stage renal disease at 3.4 times the rate of White adults, according to USRDS 2023 data 8. APOL1 risk variants (G1 and G2), carried by approximately 13% of African Americans in homozygous or compound heterozygous form, account for a significant portion of this disparity 9. Since MOTS-c is a peptide cleared through renal mechanisms, CKD prevalence in a target population affects both pharmacokinetics and safety. No renal-impairment dosing data exist for MOTS-c in any population.

MOTS-c Pharmacogenomics: What the Databases Show

Pharmacogenomic profiling should theoretically guide population-specific dosing for any metabolic peptide. For MOTS-c, the available data are remarkably thin.

PharmGKB and CPIC Status

PharmGKB, the primary pharmacogenomics knowledge base, contains no entry for MOTS-c as of May 2026 10. The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published dosing guidelines for over 25 drug-gene pairs, but mitochondrial-derived peptides have not entered this pipeline. This absence means prescribers working with MOTS-c in any population have zero pharmacogenomic guidance to reference.

mtDNA Polymorphisms in the MOTS-c Coding Region

A 2016 analysis by Fuku et al. Identified a specific mtDNA variant (m.1382A>C) within the MOTS-c coding region that was associated with type 2 diabetes risk in a Japanese cohort 11. This SNP produces a K14Q amino acid substitution in the MOTS-c peptide. The allele frequency of m.1382A>C differs by haplogroup. L-lineage haplogroups carry a distinct constellation of nearby polymorphisms that could affect MOTS-c folding, receptor binding, or half-life 2. No functional study has characterized MOTS-c peptide variants specific to African-lineage mitochondrial haplotypes.

G6PD Deficiency Interaction Concern

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects approximately 12% of African American males 12. G6PD is the rate-limiting enzyme in the pentose phosphate pathway, which intersects with the folate-methionine cycle that MOTS-c regulates. Theoretically, MOTS-c's metabolic effects on one-carbon metabolism could alter redox balance in G6PD-deficient individuals. This interaction has not been studied in vitro or in vivo, but the prevalence of G6PD deficiency in African ancestry populations makes it a relevant safety consideration that trial designers should address.

Preclinical Evidence and Its Translational Limits

The preclinical MOTS-c literature is small. It demonstrates biological plausibility for metabolic benefit, but the translational gap to Black/African ancestry humans is wide.

Murine Data

Lee et al. (2015) demonstrated that MOTS-c administration in C57BL/6 mice prevented age-dependent and high-fat-diet-induced insulin resistance, reduced obesity, and improved glucose tolerance 1. A follow-up study by the same group showed MOTS-c translocates to the nucleus under metabolic stress and regulates adaptive gene expression through AMPK-dependent and AMPK-independent pathways 13.

The Inbred Strain Problem

C57BL/6 mice are genetically homogeneous. Their mitochondrial genome is fixed. This means all MOTS-c efficacy data come from a single mitochondrial haplotype context. A 2019 study in Nature Genetics demonstrated that mitochondrial-nuclear genome interactions significantly alter metabolic phenotypes in mice, with different mtDNA backgrounds producing different responses to the same metabolic intervention 14. Extrapolating C57BL/6 MOTS-c data to humans carrying L-lineage mtDNA introduces a confound that has not been addressed.

Human Observational Data

A cross-sectional study by Ramanjaneya et al. (2019) measured circulating MOTS-c levels in humans and found that plasma MOTS-c was lower in individuals with type 2 diabetes and obesity compared to healthy controls 15. The study cohort was predominantly Middle Eastern. No large observational study has measured endogenous MOTS-c levels in a Black or African ancestry cohort. Without baseline MOTS-c level data stratified by ancestry, it is impossible to determine whether exogenous supplementation would restore levels to the same target range across populations.

Dosing Considerations for Black / African Ancestry Patients

No clinical dosing protocol for MOTS-c has been published for any population. The peptide is available through compounding pharmacies and research-use channels, but standardized dosing remains undefined.

What Current Practice Looks Like

Anecdotal clinical use of MOTS-c typically involves subcutaneous injection at doses ranging from 5 mg to 10 mg administered two to three times per week. These protocols derive from extrapolation of murine pharmacokinetic data and early human tolerability observations. They were not developed using pharmacokinetic modeling in diverse populations.

Why Ancestry-Specific Dosing May Be Needed

Three factors converge to suggest that Black/African ancestry patients may require different dosing. First, mtDNA haplogroup-driven differences in endogenous MOTS-c expression or peptide structure could alter the dose-response curve 11. Second, higher baseline insulin resistance means the pharmacodynamic target (AMPK activation sufficient to normalize glucose handling) may require a different threshold dose 5. Third, the higher prevalence of CKD and reduced GFR in this population could slow peptide clearance and increase exposure at standard doses 8.

The Precedent from Other Metabolic Therapies

Metformin, the most widely prescribed insulin sensitizer, shows comparable HbA1c reduction across racial groups in large trials like UKPDS and DPP 16. GLP-1 receptor agonists also appear to produce similar weight loss across racial subgroups in STEP-1 (N=1,961) and SURMOUNT-1 (N=2,539), though Black participants represented only 4-6% of enrollment 17. MOTS-c, as a mitochondrially encoded peptide whose genetics differ fundamentally by ancestry, may not follow this pattern. The molecule itself varies with the patient's maternal lineage in a way that metformin and semaglutide do not.

What Needs to Happen: Research Priorities

Immediate Needs

Measurement of endogenous circulating MOTS-c in a large, ancestry-diverse cohort (minimum N=500 per group) with paired mtDNA haplogroup data. The NIH All of Us Research Program, which has enrolled over 370,000 participants with 46% from underrepresented backgrounds, provides an existing biobank that could support this work 18.

Medium-Term Needs

Phase I pharmacokinetic studies of exogenous MOTS-c that include mandatory stratification by self-reported race and confirmed mtDNA haplogroup. The FDA's 2020 guidance on enhancing diversity in clinical trials specifically calls for enrollment strategies that ensure adequate representation of Black and African American participants 19.

Long-Term Needs

Ethnicity-stratified efficacy endpoints in any future MOTS-c Phase II/III trial. The Endocrine Society's 2023 position statement on health disparities emphasized that endocrine therapies require outcomes data across racial groups to ensure equitable prescribing 20.

Clinical Guidance Until Evidence Emerges

Clinicians considering MOTS-c for Black or African ancestry patients should document that no ethnicity-specific efficacy or safety data exist. Informed consent should explicitly state this evidence gap. Baseline labs should include fasting glucose, fasting insulin, HOMA-IR, HbA1c, comprehensive metabolic panel with eGFR (using the 2021 CKD-EPI creatinine equation, which removed the race coefficient per KDIGO recommendation) 21, and G6PD activity in males. Monitor glucose parameters at 4-week intervals. Consider starting at the lower end of anecdotal dosing ranges (5 mg twice weekly) and titrating based on metabolic response and renal function.